IDEXX Laboratories — 8/10
IDEXX Laboratories is the dominant pure-play on the secular pet-healthcare / pet-humanization theme, expressed through veterinary diagnostics. The franchise runs a razor/blade model: a large installed base of in-clinic analyzers (IDEXX VetLab) plus the largest North American reference-lab network pull through recurring, high-margin consumables and test volume. Roughly 79% of revenue is recurring CAG diagnostic revenue. In 26Q1, revenue grew +14.3% YoY — a clean, sustained acceleration off the 25Q1 trough — with gross margin expanding to a record 63.4%, a share count shrinking ~2.2%/yr on buybacks, and free cash flow positive and growing.
The core tension: IDXX is a near-textbook high-quality compounder that clears the oligopoly gate decisively, holding ~60-65% of the NA in-clinic / point-of-care companion-animal diagnostics market (its primary and largest segment), a duopoly position with Mars/Antech in NA reference labs, and the global standard in Water (Colilert). That dominance, growing FCF, and a multi-year beat-and-raise management track record clear all three quality-gate criteria (0 NOs). The composite is held to 8 by a demanding ~38x FY26 P/E — roughly 2x its closest premium peer Zoetis — that leaves no margin of safety, and by a management-vs-Street divergence that is real but only verbal (no confirming insider buying).
| CEO | Mike Erickson (from May 2026) | Revenue Growth | Accelerating (+14.3% 26Q1) |
| Secular Tailwind | Pet healthcare / humanization | FCF Trajectory | Growing, share count declining |
| Recurring Revenue | ~79% CAG Dx recurring | FYE | December 31 |
| Quality Gate | PASS (0 NOs) | Margin Trend | Expanding |
| Dimension | Score | Weight | Weighted |
|---|---|---|---|
| Financial Trends | 9 | 25% | 2.25 |
| Thematic Exposure | 9 | 35% | 3.15 |
| Management Quality | 7 | 20% | 1.40 |
| Investor Sentiment (Inverted) | 6 | 5% | 0.30 |
| Concerns / Risks | 6 | 15% | 0.90 |
| Composite | 100% | 8 |
A genuine A-tier quality compounder with 9/10 financials and 9/10 thematics — accelerating high-quality recurring revenue (+14.3% YoY in 26Q1, CAG Dx recurring +14.1%), durable gross-margin expansion to a record 63.4%, a steadily shrinking share count, and growing free cash flow. It rates 8/10 on the strength of a dominant, oligopolistic franchise and a 6-of-6 beat-and-raise management team, tempered by two lower-15%-weight dimensions: (1) an inverted-sentiment divergence that is real but only verbal and unconfirmed by insider buying (Sentiment 6/10), and (2) a demanding ~38x FY26 P/E that leaves no margin of safety (Concerns/Risks 6/10).
Quality gate: PASS (0 NOs). Oligopoly YES (~60-65% NA POC share, reference-lab duopoly, Water standard). Positive & growing FCF YES ($636M FY21 to $1,057M FY25). Management 3+ year track record YES (multi-year beat-and-raise). All three clear, so no composite cap is applied — the raw weighted composite of 8 stands.
IDEXX's financial and competitive profile is genuinely top-decile: accelerating recurring revenue, expanding gross margins, growing FCF, a shrinking share count, and a dominant ~60-65% share of its core NA in-clinic diagnostics market with real pricing power (~4pts/yr) and deep razor/blade switching costs. This is exactly the "leader in a growing market" the framework rewards — and, unlike a co-leader, IDXX clears the oligopoly hard gate decisively.
The management transition (Jay Mazelsky to Executive Chair, internal EVP Mike Erickson to CEO in May 2026) is a planned, telegraphed, inside succession that preserves strategy — the mechanical −1 red-flag docks the score to 7/10 but is not a quality knock.
The binding constraint on the composite is price: at ~37.9x FY2026E P/E (roughly 2x premium peer Zoetis) and ~27x EV/EBITDA, the multiple already capitalizes much of the franchise quality, leaving no cushion for any organic-growth wobble. Combined with a management-vs-Street divergence the market openly debates (rather than misses), the setup is a superb business at a demanding price — an 8, not an 8-plus.